keyword
MENU ▼
Read by QxMD icon Read
search

New oral anticoagulants

keyword
https://www.readbyqxmd.com/read/29455033/thromboprophylaxis-for-ambulatory-surgery-results-from-a-prospective-national-cohort
#1
Charles Marc Samama, Dan Benhamou, Frédéric Aubrun, Jean-Luc Bosson, Pierre Albaladejo
BACKGROUND: Venous thromboembolism (VTE) prophylaxis is not always part of the usual care of ambulatory surgery patients, and few guidelines are available. OBJECTIVES: To collect data on the application of VTE prophylaxis in ambulatory patients. DESIGN: The OPERA study is a large national survey performed in 221 healthcare facilities. PATIENTS: 2174 patients who underwent one of ten selected procedures over two pre-defined days of investigation...
February 15, 2018: Anaesthesia, Critical Care & Pain Medicine
https://www.readbyqxmd.com/read/29451506/-ten-questions-on-the-management-of-patients-with-acute-pulmonary-embolism
#2
Cecilia Becattini, Cristian Mattei, Giancarlo Agnelli
Clinical management of acute pulmonary embolism has changed over the years based on new evidence on diagnosis, prognostic stratification and treatment. The increasing availability of computed tomography angiography has made the diagnosis faster and accurate, although with some concern on radiation exposure and potential for overdiagnosis. The efficacy and safety of simple-to-use oral anticoagulant agents acting as selective direct inhibitors of coagulation certainly offer considerable benefits to the patients...
January 2018: Giornale Italiano di Cardiologia
https://www.readbyqxmd.com/read/29441984/direct-oral-anticoagulants-in-real-clinical-practice-analysis-of-patient-characteristics-and-prescribing-patterns-in-a-large-teaching-hospital
#3
B Kováčová, J Červeňová
Direct oral anticoagulants (DOACs) became rapidly accepted as an alternative to warfarin in the prevention of stroke in atrial fibrillation and prophylaxis of thromboembolic events. Their safety and efficacy have been well documented in several studies, however, as with any new drug, use in real-world population often reveals risk factors that may affect treatment outcomes. The aim of the study was to determine the prescribing patterns and analyse patient characteristics to identify incidence of selected factors (age, weight, comorbidities and interacting medication) that may affect DOAC safety and efficacy...
September 1, 2017: Die Pharmazie
https://www.readbyqxmd.com/read/29432304/anemia-in-adolescents-and-young-adult-patients-with-congenital-heart-disease
#4
Juan L Rodríguez-Hernández, Fayna Rodríguez-González, Efrén Martínez-Quintana
INTRODUCTION: Despite anemia in acquired heart disease being a common problem, little is known in patients with congenital heart disease (CHD). METHODS: In total, 544 consecutive stable noncyanotic CHD patients were studied to determine demographic, clinical, and analytic parameters. Anemia was defined as a condition in which hemoglobin concentration was <13 g/dL in male individuals and <12 g/dL in female individuals. RESULTS: In total, 49 (9%) CHD patients had anemia...
February 9, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/29424698/a-promising-oral-fucoidan-based-antithrombotic-nanosystem-development-activity-and-safety
#5
Luiz Cláudio Rodrigues Pereira da Silva, Valerio Todaro, Flávia Almada do Carmo, Flavia Serra Frattani, Valeria Pereira de Sousa, Carlos Rangel Rodrigues, Plínio Cunha Sathler, Lucio Mendes Cabral
Fucoidan-loaded nanoparticles emerge as great candidates to oral anticoagulant therapy, due to increasing of bioavailability and circulation time of this natural anticoagulant. Crosslink between chitosan chains are performed using glutaraldehyde to confer higher gastric pH resistance to nanoparticle matrices. In this work, chitosan-fucoidan nanoparticles, without (NpCF) and with glutaraldehyde crosslink (NpCF 1% and NpCF 2%), were prepared to evaluate their anticoagulant, antithrombotic and hemorrhagic profile...
February 9, 2018: Nanotechnology
https://www.readbyqxmd.com/read/29417080/new-indications-for-dabigatran-a-suggestion-from-a-drug-use-evaluation-study
#6
Farzaneh Ashrafi, Najmeh Rezaie, Sarah Mousavi
Objective: Dabigatran etexilate is a novel oral anticoagulant with several advantages over warfarin such as no need for routine monitoring and fewer drug interactions. This drug was added to our hospital's formulary in 2012. The objective of this study was to assess the rational drug use of dabigatran at a large teaching hospital. Methods: A prospective cross-sectional study was performed from November to June 2015 at Alzahra teaching hospital, Isfahan, Iran. All patients who received at least one dose of dabigatran were eligible for inclusion...
October 2017: Journal of Research in Pharmacy Practice
https://www.readbyqxmd.com/read/29407632/what-have-we-learned-from-real-world-noac-studies-in-venous-thromboembolism-treatment
#7
REVIEW
Jan Beyer-Westendorf
Venous thromboembolism (VTE) remains a substantial clinical and health-economic burden worldwide and effective anticoagulant treatment is necessary immediately after VTE is suspected to reduce short- and long-term VTE related morbidity and mortality. For decades, low molecular weight heparin (LMWH), fondaparinux and Vitamin K antagonists (VKAs) have been the standard of anticoagulant therapy for VTE patients but these treatment options had clinically relevant drawbacks and limitations. The introduction of non-VKA oral anticoagulants (NOACs) that specifically inhibit either thrombin or factor Xa have resolved many of these drawbacks because these new compounds exhibit a rapid onset and offset of action, fewer food and drug interactions and a predictable anticoagulant effect...
January 26, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29402281/combining-value-of-information-analysis-and-ethical-argumentation-in-decisions-on-participation-of-vulnerable-patients-in-clinical-research
#8
Gert J van der Wilt, Janneke P C Grutters, Angela H E M Maas, Herbert J A Rolden
BACKGROUND: The participation of vulnerable patients in clinical research poses apparent ethical dilemmas. Depending on the nature of the vulnerability, their participation may challenge the ethical principles of autonomy, non-maleficence, or justice. On the other hand, non-participation may preclude the building of a knowledge base that is a prerequisite for defining the optimal clinical management of vulnerable patients. Such clinical uncertainty may also incur substantial economic costs...
February 5, 2018: BMC Medical Ethics
https://www.readbyqxmd.com/read/29399533/pathogenesis-of-thrombosis-cellular-and-pharmacogenetic-contributions
#9
REVIEW
Dileep D Monie, Emma P DeLoughery
Our understanding of thrombosis formation has evolved significantly ever since physician Rudolf Virchow proposed his "triad" theory in 1856. Modern science has elucidated the mechanisms of stasis, hypercoagulability, and endothelial dysfunction. Today, we have a firm understanding of the key molecular factors involved in the coagulation cascade and fibrinolytic system, as well as the underlying genetic influences. This knowledge of cellular and genetic contributors has been translated into diverse pharmaceutical interventions...
December 2017: Cardiovascular Diagnosis and Therapy
https://www.readbyqxmd.com/read/29399524/statins-as-a-preventative-therapy-for-venous-thromboembolism
#10
REVIEW
Alex Wallace, Hassan Albadawi, Peter Hoang, Andrew Fleck, Sailendra Naidu, Grace Knuttinen, Rahmi Oklu
The anti-inflammatory effects of statins have likely not been used to their fullest extent, particularly in reducing venous thromboembolic events. Current therapy for thrombotic events hinges on anticoagulation via heparin, warfarin or new oral anticoagulants. Interventional procedures with thrombectomy may also play a critical role. Unfortunately, thrombotic events can occur and recur despite meticulous anticoagulation therapy. Venous thromboembolism (VTE) includes both deep vein thrombosis (DVT) and pulmonary embolism (PE), two complicated and prevalent diseases that can cause chronic disease states such as post-thrombotic syndrome (PTS)...
December 2017: Cardiovascular Diagnosis and Therapy
https://www.readbyqxmd.com/read/29395759/evaluation-of-activated-charcoal-and-lipid-emulsion-treatment-in-model-of-acute-rivaroxaban-toxicity
#11
Sinan Cem Uzunget, Togay Evrin, Sezen Baglan Uzunget, Zamir Kemal Ertürk, Egemen Akıncıoğlu, Saffet Özdemir, Atila Korkmaz
AIM: Reducing or reversing the toxicity effects of new oral anticoagulants is an important question.The purpose of the present study is to evaluate the effect of lipid emulsion (LE) and Activated Charcoal (AC) therapy on the intoxication of rivaroxaban, on mice. METHODS: Adult male Balb/c mice weighing approximately 30g were used in the study. Seven groups were assigned, with six mice in each group. Groups were defined; given only rivaroxaban, given only LE, given only AC, after the administration of rivaroxaban LE applied group in the 1st hour, after the administration of rivaroxaban LE applied group in the 3rd hour, after the administration of rivaroxaban AC applied group in the1st hour, after the administration of rivaroxaban AC applied group in the 1st hour and LE applied group in the 3rd hour...
December 14, 2017: American Journal of Emergency Medicine
https://www.readbyqxmd.com/read/29378352/atherothrombosis-and-thromboembolism-position-paper-from-the-second-maastricht-consensus-conference-on-thrombosis
#12
H M H Spronk, T Padro, J E Siland, J H Prochaska, J Winters, A C van der Wal, J J Posthuma, G Lowe, E d'Alessandro, P Wenzel, D M Coenen, P H Reitsma, W Ruf, R H van Gorp, R R Koenen, T Vajen, N A Alshaikh, A S Wolberg, F L Macrae, N Asquith, J Heemskerk, A Heinzmann, M Moorlag, N Mackman, P van der Meijden, J C M Meijers, M Heestermans, T Renné, S Dólleman, W Chayouâ, R A S Ariëns, C C Baaten, M Nagy, A Kuliopulos, J J Posma, P Harrison, M J Vries, H J G M Crijns, E A M P Dudink, H R Buller, Y M C Henskens, A Själander, S Zwaveling, O Erküner, J W Eikelboom, A Gulpen, F E C M Peeters, J Douxfils, R H Olie, T Baglin, A Leader, U Schotten, B Scaf, H M M van Beusekom, L O Mosnier, L van der Vorm, P Declerck, M Visser, D W J Dippel, V J Strijbis, K Pertiwi, A J Ten Cate-Hoek, H Ten Cate
Atherothrombosis is a leading cause of cardiovascular mortality and long-term morbidity. Platelets and coagulation proteases, interacting with circulating cells and in different vascular beds, modify several complex pathologies including atherosclerosis. In the second Maastricht Consensus Conference on Thrombosis, this theme was addressed by diverse scientists from bench to bedside. All presentations were discussed with audience members and the results of these discussions were incorporated in the final document that presents a state-of-the-art reflection of expert opinions and consensus recommendations regarding the following five topics: 1...
February 2018: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/29376959/-clinical-experience-with-the-use-of-rivaroxaban-in-the-treatment-of-cancer-patients-with-venous-thrombosis
#13
P F Kravtsov, S E Katorkin, M A Melnicov
The urgency of the problem. The incidence of various thromboembolic complications in patients with oncopathology reaches 5-12%. When treating VTE in patients with oncology it is necessary to choose between two generally recognized alternatives. The recommended two-component scheme of the initiating phase of anticoagulant therapy with subsequent long-term admission of VKA is fraught with the development of clinically significant bleeding during the initial selection of the dose of warfarin and an increased risk of recurrence of VTE...
2018: Khirurgiia
https://www.readbyqxmd.com/read/29374047/use-of-direct-oral-anticoagulants-in-canadian-primary-care-practice-2010-2015-a-cohort-study-from-the-canadian-primary-care-sentinel-surveillance-network
#14
Finlay A McAlister, Scott Garrison, Leanne Kosowan, Justin A Ezekowitz, Alexander Singer
BACKGROUND: As questions have been raised about the appropriateness of direct oral anticoagulant (DOAC) dosing among outpatients with atrial fibrillation, we examined this issue in patients being managed by primary care providers. METHODS AND RESULTS: This was a retrospective cohort new-user study using electronic medical records from 744 Canadian primary care clinicians. Potentially inappropriate DOAC prescribing was defined as prescribing lower or higher doses than those recommended by guidelines for patients with nonvalvular atrial fibrillation...
January 26, 2018: Journal of the American Heart Association
https://www.readbyqxmd.com/read/29372411/-s1%C3%A2-guideline-austrian-consensus-for-anticoagulation-in-the-context-of-atrial-fibrillation-ablation
#15
Martin Martinek, Marianne Gwechenberger, Daniel Scherr, Clemens Steinwender, Markus Stühlinger, Helmut Pürerfellner, Franz Xaver Roithinger, Lukas Fiedler
In summary, uninterrupted oral antikoagulation can be recommended, with different recommendation classes and levels of evidence, for both, VKA and NOAC therapy, in the framework of PVI. Even with low CHA2DS2 VASc scores, OAK is indicated 3-4 weeks before and 8 weeks after the procedure. Periinterventional bridging with heparins should be avoided due to increased bleeding events.The present Consensus provides recommendations on the current state of knowledge and has been prepared exclusively by members of the Rhythmology Working Group of the Austrian Cardiological Society who have great practical experience in catheter ablation and peri-interventional OAK in patients with atrial fibrillation...
January 25, 2018: Wiener Klinische Wochenschrift
https://www.readbyqxmd.com/read/29371284/comparative-effectiveness-of-novel-oral-anticoagulants-in-uk-patients-with-non-valvular-atrial-fibrillation-and-chronic-kidney-disease-a-matched-cohort-study
#16
Simone Y Loo, Janie Coulombe, Sophie Dell'Aniello, James M Brophy, Samy Suissa, Christel Renoux
OBJECTIVES: To evaluate the effectiveness and safety of novel oral anticoagulants (NOACs) compared with vitamin K antagonists (VKAs) among patients with non-valvular atrial fibrillation (NVAF), particularly those with chronic kidney disease (CKD). DESIGN: Population-based matched cohort study. SETTING: Over 670 primary care practices in the UK, contributing to the Clinical Practice Research Datalink. PARTICIPANTS: Up to 6818 adult patients newly treated with NOACs between 2011 and 2016, matched 1:1 to new users of VKAs on age, sex and high-dimensional propensity score...
January 24, 2018: BMJ Open
https://www.readbyqxmd.com/read/29370290/incidence-of-venous-thromboembolism-in-korea-from-2009-to-2013
#17
Junshik Hong, Ju Hyun Lee, Ho-Young Yhim, Won-Il Choi, Soo-Mee Bang, Heeyoung Lee, Doyeun Oh
The incidence of venous thromboembolism (VTE) is lower in Asian populations than in Western populations. The objective of the present study was to evaluate the annual age- and sex-adjusted incidence (ASR) of VTE from 2009 to 2013 in South Korea. In addition, annual change in the pattern of VTE treatment during the study period was estimated because a new direct oral anticoagulant (DOAC) had become available and was covered by health insurance in Korea beginning in January 2013. VTE cases from 2009 to 2013 were retrospectively identified based on both diagnostic and medication codes of anticoagulants used for initial treatment using the Korean Health Insurance Review and Assessment Service (HIRA) databases...
2018: PloS One
https://www.readbyqxmd.com/read/29362869/antiplatelet-and-anticoagulant-agents-in-vitreoretinal-surgery-a-prospective-multicenter-study-involving-804-patients
#18
Cyril Meillon, Pierre Henry Gabrielle, Maxime Luu, Ludwig S Aho-Glele, Alain M Bron, Catherine Creuzot-Garcher
PURPOSE: To assess the rate of hemorrhagic complications after vitreoretinal surgery and the influence of antithrombotic agents. METHODS: Hemorrhagic complications of vitreoretinal procedures performed in seven ophthalmologic centers on patients treated or not treated with antiplatelet (AP) or anticoagulant (AC) agents were prospectively collected. Patients' characteristics, surgical techniques, and complications were recorded during surgery and for 1 month after...
January 23, 2018: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29360144/agreement-between-coding-schemas-used-to-identify-bleeding-related-hospitalizations-in-claims-analyses-of-nonvalvular-atrial-fibrillation-patients
#19
Craig I Coleman, Tatsiana Vaitsiakhovich, Elaine Nguyen, Erin R Weeda, Nitesh A Sood, Thomas J Bunz, Bernhard Schaefer, Anna-Katharina Meinecke, Daniel Eriksson
BACKGROUND: Schemas to identify bleeding-related hospitalizations in claims data differ in billing codes used and coding positions allowed. We assessed agreement across bleeding-related hospitalization coding schemas for claims analyses of nonvalvular atrial fibrillation (NVAF) patients on oral anticoagulation (OAC). HYPOTHESIS: We hypothesized that prior coding schemas used to identify bleeding-related hospitalizations in claim database studies would provide varying levels of agreement in incidence rates...
January 23, 2018: Clinical Cardiology
https://www.readbyqxmd.com/read/29346128/management-of-heavy-menstrual-bleeding-during-direct-oral-anticoagulant-therapy-for-recurrent-venous-thromboembolism-a-case-report
#20
Michela Giustozzi, Maria C Vedovati, Giancarlo Agnelli
: A high risk of venous thromboembolism (VTE) recurrence requires extended anticoagulation but limits the options to control heavy menstrual bleeding (HMB) in women of reproductive age. We report the management of HMB in a 48-year-old woman with a history of menometrorrhagia, recurrent VTE and multiple VTE risk factors. Due to the occurrence of HMB during extended rivaroxaban treatment, the presence of a uterine fibroid and the contraindication to interrupt anticoagulation for high risk of VTE recurrence, she received hormonal treatment first with a gonadotropin-releasing hormone agonist and then with progestin...
January 15, 2018: Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis
keyword
keyword
16255
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"